Sökning: onr:"swepub:oai:gup.ub.gu.se/213006" >
Pathways to Alzheim...
Pathways to Alzheimer's disease
-
Hardy, J. (författare)
-
- Bogdanovic, N. (författare)
- Karolinska Institutet
-
- Winblad, B. (författare)
- Karolinska Institutet
-
visa fler...
-
Portelius, E. (författare)
-
- Andreasen, N. (författare)
- Karolinska Institutet
-
- Cedazo-Minguez, A. (författare)
- Karolinska Institutet
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
visa färre...
-
(creator_code:org_t)
- 2014-01-27
- 2014
- Engelska.
-
Ingår i: Journal of Internal Medicine. - : Wiley. - 0954-6820 .- 1365-2796. ; 275:3, s. 296-303
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Recent trials of anti-amyloid agents have not produced convincing improvements in clinical outcome in Alzheimer's disease; however, the reason for these poor or inconclusive results remains unclear. Recent genetic data continue to support the amyloid hypothesis of Alzheimer's disease with protective variants being found in the amyloid gene and both common low-risk and rare high-risk variants for disease being discovered in genes that are part of the amyloid response pathways. These data support the view that genetic variability in how the brain responds to amyloid deposition is a potential therapeutic target for the disease, and are consistent with the notion that anti-amyloid therapies should be initiated early in the disease process. © 2014 The Association for the Publication of the Journal of Internal Medicine.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Nyckelord
- Alzheimer's disease
- Amyloid
- Cell biology
- Genetics
- Tau
- amyloid precursor protein
- apolipoprotein E
- avagacestat
- bapineuzumab
- clusterin
- gamma secretase inhibitor
- immunoglobulin G1 antibody
- Notch3 receptor
- presenilin
- semagacestat
- solanezumab
- Alzheimer disease
- article
- cellular distribution
- cerebrospinal fluid level
- cholesterol metabolism
- cholesterol synthesis
- cholesterol transport
- clinical pathway
- complement classical pathway
- drug clearance
- follow up
- genetic analysis
- genetic association
- genetic variability
- innate immunity
- nonhuman
- pathogenesis
- phase 1 clinical trial (topic)
- phase 2 clinical trial (topic)
- phase 3 clinical trial (topic)
- priority journal
- randomized controlled trial (topic)
- risk factor
- signal transduction
- Amyloid beta-Peptides
- Brain
- Early Medical Intervention
- Genetic Predisposition to Disease
- Humans
- Immunotherapy
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas